\n Post this
\n <\/a><\/p>\n
“INHILO+ represents our approach to professional aesthetic product development through differentiated formulation concepts, clinical evaluation, and collaboration with established industry partners and healthcare professionals,” said a representative of BS PHARM KOREA. “We aim to continue building a strong foundation for the long-term development of INHILO+ in both domestic and international markets.”<\/p>\n
Dual-Molecular HA Formulation Supported by Clinical Data<\/p>\n
Clinical data for INHILO+ include a manufacturer-sponsored study involving 55 subjects. The product was evaluated alongside a comparable control product through self-assessments of wrinkle improvement and overall aesthetic enhancement at Weeks 2, 12, and 24. Among subjects in the INHILO+ treatment group, 85.2% reported improvement at Week 2, followed by 67.9% at Week 12 and 55.8% at Week 24. These findings provide clinical data for the Dual-Molecular HA formulation and serve as a basis for continued product evaluation.<\/p>\n
Expanding Domestic Market Access Through Dongkook Pharmaceutical<\/p>\n
In February 2026, BS PHARM KOREA established a partnership<\/a> with Dongkook Pharmaceutical for the domestic distribution of INHILO+ in South Korea. The collaboration combines BS PHARM KOREA’s product expertise with Dongkook Pharmaceutical’s established domestic distribution capabilities, supporting broader access to INHILO+ within the Korean professional aesthetic market. The agreement represents an important commercial milestone for INHILO+ as the product builds its presence in the domestic market.<\/p>\n Expanding Clinical Insights Through Ongoing Evaluation<\/p>\n Building on the existing clinical data, BS PHARM KOREA is conducting an additional clinical evaluation<\/a> of INHILO+ in collaboration with medical professionals in South Korea. The program uses standardized treatment and follow-up conditions to observe skin quality-related parameters and participant outcomes in professional aesthetic practice. The evaluation is intended to generate additional clinical insights into the product under standardized clinical conditions. It also supports continued professional collaboration and evidence-based communication around INHILO+.<\/p>\n Advancing International Market Development<\/p>\n The domestic distribution partnership, existing clinical data, and ongoing evaluation collectively support the next stage of INHILO+’s development. As part of its international market development activities, BS PHARM KOREA will introduce INHILO+ to healthcare professionals and industry partners at Dubai Derma 2026, taking place September 8\u201310 in Dubai, United Arab Emirates. The company plans to use the congress as an opportunity to present the product’s Dual-Molecular HA concept and engage with prospective partners from international markets. BS PHARM KOREA will also continue to share updates from the ongoing clinical evaluation as follow-up assessments progress.<\/p>\n About BS PHARM KOREA<\/p>\n BS PHARM KOREA is a South Korea-based company specializing in professional aesthetic products for healthcare professionals and international distribution partners. The company supports global markets through portfolio development, clinical collaboration, participation in international medical aesthetics congresses, and long-term partnerships with distributors worldwide.<\/p>\n For more information, visit BS PHARM KOREA<\/a>.<\/p>\n Media Contact<\/p>\n Marketing Manager, BS PHARM KOREA, 82 25117185, [email\u00a0protected]<\/a>, www.bsp-korea.com<\/a><\/p>\n SOURCE BS PHARM KOREA<\/p>\n![\"\"](\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=UN39102&Transmission_Id=202609060800PR_NEWS_USPR_____UN39102&DateId=20260906\")
<\/p>\n","protected":false},"excerpt":{"rendered":"INHILO+ represents our approach to professional aesthetic product development through differentiated formulation concepts, clinical evaluation, and collaboration with…\n","protected":false},"author":2,"featured_media":144886,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[2830,73508,12728,31,2829,2828],"class_list":["post-144885","post","type-post","status-publish","format-standard","has-post-thumbnail","category-korea","tag-biotechnology","tag-bs-pharm-korea","tag-cosmetics-and-personal-care","tag-korea","tag-medical-pharmaceuticals","tag-pharmaceuticals"],"_links":{"self":[{"href":"https:\/\/www.europesays.com\/korea\/wp-json\/wp\/v2\/posts\/144885","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/korea\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/korea\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/korea\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/korea\/wp-json\/wp\/v2\/comments?post=144885"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/korea\/wp-json\/wp\/v2\/posts\/144885\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/korea\/wp-json\/wp\/v2\/media\/144886"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/korea\/wp-json\/wp\/v2\/media?parent=144885"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/korea\/wp-json\/wp\/v2\/categories?post=144885"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/korea\/wp-json\/wp\/v2\/tags?post=144885"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}